Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

被引：103
|
作者：
Russell-Jones, David [1 ]
机构：
[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford GU2 7XX, Surrey, England
来源：
MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2009年 / 297卷 / 1-2期
关键词：
GLP-1; analogue; Hypoglycaemia; Body weight; Systolic blood pressure; GLUCAGON-LIKE PEPTIDE-1; GLYCEMIC CONTROL; GENE-EXPRESSION; BETA-CELLS; DERIVATIVES; WEIGHT; SULFONYLUREA; NN2211;
D O I：
10.1016/j.mce.2008.11.018
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical Studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：137 / 140
页数：4
相关论文
共 50 条
  • [41] Liraglutide, a Once-Daily Human GLP-1 Analog, Is Equally Effective and Tolerated Independent of Administration Time (Morning vs Evening)
    Kaku, Kohei
    Rasmussen, Mads
    Katayama, Yasuyuki
    Seino, Yutaka
    DIABETES, 2009, 58 : A144 - A144
  • [42] Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2013, 37 : 322 - 322
  • [43] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
    Colagiuri, Steven
    Frid, Anders
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Vaag, Allan
    DIABETES, 2008, 57 : A164 - A165
  • [44] The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
    Christensen, Mikkel
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (04) : 513 - 525
  • [45] The once-daily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic action mechanisms
    Shimoda, M.
    Kanda, Y.
    Tawaramoto, K.
    Hashiramoto, M.
    Matsuki, M.
    Kaku, K.
    DIABETOLOGIA, 2008, 51 : S210 - S210
  • [46] Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
    Plutzky, J.
    Garber, A.
    Toft, A. D.
    Poulter, N. R.
    DIABETOLOGIA, 2009, 52 : S299 - S300
  • [47] Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin
    Montanya Mias, E.
    Cuddihy, R.
    Pratley, R.
    Hammer, M.
    Thomsen, A.
    Davies, M. J.
    DIABETOLOGIA, 2010, 53
  • [48] The Relationship between Pharmacokinetics of the Once-Daily Human GLP-1 Analog Liraglutide and Pharmacodynamic Effects on Glycemia, Gastric Emptying and Energy Intake
    Flint, Anne
    Hindsberger, Charlotte
    DIABETES, 2010, 59 : A420 - A420
  • [49] Tritium labelling of the GLP-1 analogue liraglutide
    Larsen, Uffe S.
    Hansen, Heidi B.
    Dahl, Anne-Metre
    Sorensen, Lone
    Kristensen, Jesper B.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (5-6): : 549 - 550
  • [50] Liraglutide-A Novel GLP-1 Analogue
    Kalra, Sanjay
    Kalra, Bharti
    Sharma, Amit
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2009, 3 (03) : 200 - 204
12345